XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeGlobeNewsWire • 09/26/23
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic CancerGlobeNewsWire • 08/30/23
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical TrialGlobeNewsWire • 08/08/23
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its SharesGlobeNewsWire • 05/17/23
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeGlobeNewsWire • 04/17/23
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal CancerGlobeNewsWire • 10/13/22
XBiotech Announces Successful Completion of Phase I portion of Pancreatic Cancer StudyGlobeNewsWire • 06/20/22
XBiotech Announces French National Agency (ANSM) Approval and National Cancer Institute (INSA) funding to Support Phase I/II/III Clinical Study for Natrunix™ in Combination with Trifluridine/Tipiracil (TASKIN) for Treatment of Metastatic Colorectal CancerGlobeNewsWire • 04/28/22
XBiotech Announces First Patient Enrolled in Phase I Clinical Trial for Novel Arthritis Therapy Natrunix-SQGlobeNewsWire • 01/26/22
XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic CancerGlobeNewsWire • 06/23/21
XBiotech To Test New Drug Candidate Combined With Approved Treatment In Pancreatic CancerBenzinga • 04/19/21
FDA Gives Go-Ahead for XBiotech's Candidate Therapy for Phase I/II Double-blind Placebo Controlled Study in Pancreatic CancerGlobeNewsWire • 04/19/21
XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging StrainGlobeNewsWire • 01/21/21
XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke TherapyGlobeNewsWire • 01/19/21